Amphibian collagen-based nano-carriers for enhanced VMS delivery
Transforming discarded American bullfrog skins into collagen-based nano-carriers to enhance VMS efficacy. This sustainable system boosts nutrient bioavailability by 40-60% and offers superior thermostability, suitable for tablets, gummies, and liquids.
Overview
Cuprina Holdings presents an innovative approach to enhancing vitamin and mineral supplement (VMS) delivery by utilizing amphibian collagen-based nano-carriers derived from discarded American bullfrog skins. This technology transforms food waste into a valuable resource, producing bioactive peptides and nanoparticles that encapsulate essential nutrients like iron, zinc, and fat-soluble vitamins. The nano-carriers increase nutrient bioavailability by 40-60% through gastric protection, pH-responsive intestinal release, and improved cellular uptake, ensuring greater efficacy and reduced side effects in VMS applications. The system is GRAS-compliant and offers superior thermostability compared to marine collagen, making it suitable for integration into tablets, gummies, and liquid supplements.
Technical specifications
- Key features:
- Nano-carriers sized 30-35 nm for efficient nutrient encapsulation
- Enhanced thermostability (+15°C) and dual solubility for diverse nutrient compatibility
- Reduction of food waste by diverting over 10 metric tons annually
- Compatibility with various VMS formats (tablets, gummies, liquids)
- Achieves ≥90% nutrient stability during storage
- Production process:
- Enzymatic hydrolysis for collagen extraction and peptide purification
- Development and optimization of collagen nanoparticles for nutrient encapsulation
- Stability and compatibility testing with VMS ingredients
- In vitro studies for bioavailability and digestive protection
Technology readiness level
The technology is currently at TRL 3, indicating an experimental proof of concept. Future plans involve scaling up production, conducting in vitro bioavailability studies, safety assessments, and preparing for GRAS/food safety approval, followed by market testing with prototype VMS products.
About Cuprina Holdings
Cuprina Holdings is a Singapore-based biomedical and biotechnology company focused on harnessing entomology-driven solutions for healthcare, agriculture, and waste management. Its primary medical innovation is MEDIFLY, a bio-dressing therapy utilizing live, medical-grade Lucilia cuprina maggots. These products are designed to clean wound beds and treat chronic wounds, offering a clinically effective and cost-conscious alternative to traditional debridement methods. By integrating biological insights into industrial processes, the company also explores broader applications for its technologies in sustainable development and circular economy solutions.
The company serves healthcare providers, clinics, and hospitals by providing end-to-end wound care solutions intended to improve patient quality of life and reduce the frequency of amputations. Their medical products have demonstrated significant clinical efficacy in local studies, including high rates of limb salvage and wound closure for complex patient populations. Through its leadership in biotechnology and insect-based applications, Cuprina addresses critical medical challenges while simultaneously expanding its capabilities into urban farming and sustainable resource management, aiming to build a future-fit organization that benefits both communities and the planet.
Inquire about this partnering listing
Industry applications
delivered to your inbox.